Меню
КартаВръзкиТемиБългарияНощта (K-TRIO)Мария Склодовска-КюриЗа ученициЗа учителиМетодологияИзненадай ме
H2020Обмен на изследователи2021–2025

diaRNAgnosis · A novel platform for the direct profiling of circulating cell-free ribonucleic acids in biofluids

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период
2021-01-01 → 2025-05-31
Финансиране от ЕС
759 000 €
Участници
10
Схема
MSCA-RISE

Линиите свързват координатора с партньорите.

Накратко на български

Свободните РНК молекули в кръвта и урината се анализират за откриване на специфични маркери за рак на простатата и тестовисите тумори. Това помага за по-ранна и точна диагностика, като намалява нуждата от инвазивни биопсии.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

A novel platform for the direct profiling of circulating cell-free ribonucleic acids in biofluids

Despite extensive research into circulating cell-free RNAs (ccfRNAs), especially microRNAs (miRNAs), their potential as non-invasive cancer biomarkers has not yet translated into routine clinical use. This gap stems from high costs, complex protocols, and a lack of standardised, scalable detection methods—factors that hinder early and reliable diagnosis of testicular germ cell tumours (TGCTs) and prostate cancer (PCa). Early detection is critical. TGCTs are the most common cancer in young men, while PCa is a major cause of cancer-related deaths in older men. Current diagnostic delays often lead to advanced disease and costly, aggressive treatments. Using ccfRNA profiles from blood or urine could enable earlier, more accurate diagnoses, reduce reliance on invasive biopsies, and support personalised treatment. The diaRNAgnosis project addresses these challenges through three key objectives: identifying miRNA signatures for TGCT and PCa, developing a benchtop reader (ODG platform) for rapid, amplification-free ccfRNA detection using dynamic chemical labelling and Silicon Photomultiplier technology, and validating the system with real patient samples. By combining biomarker discovery with innovative sensing and robust clinical validation, diaRNAgnosis aims to deliver a practical, cost-effective liquid biopsy platform that transforms cancer diagnostics and improves patient outcomes.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Circulating cell-free ribonucleic acids (ccfRNAs) represent an emerging and important class of molecules, able to provide significant clinical relevance as novel screening, prognostic and therapy monitoring biomarkers in cancer. Through analysing specific ccfRNAs, different cancers can be accurately correlated for type and stage. Sadly, despite extensive academic and clinical research identifying and validating in limited clinical trials, ccfRNAs have not yet entered the field of clinical diagnostics. This is amongst others because the current analytical methods remain less than satisfactory, and until now ccfRNA detection remains therefore challenging, costly, and requires elaborate multi-step sample preparations. Prompted by these current analytical limitations, two innovative EU companies, DESTINA Genomica SL (Spain) and OPTOELETTRONICA ITALIA SRL (Italy) have developed the “ODG Platform” for direct quantitative measurement of circulating RNA molecules. The diaRNAgnosis project objective is to complete development of the ODG platform, delivering reliable and robust detection of novel ccfRNA signatures that could be linked to specific cancer types. To ensure timely delivery and success of the diaRNAgnosis project, DESTINA and OPTOI have considered and invited partners who they believe will add real value to the consortium. These are the Spanish company NanoGetic SL (specializing in nanotechnologies); three key academic research groups from the Universities of Trento and Catania (Italy), Granada (Spain); as well as the Princess Máxima Center (The Netherlands). This new pan-European, multidisciplinary and intersectoral team will develop a reliable and innovative method and platform to identify cancer biomarkers in liquid biopsies. The research collaboration will address the need to perform high sensitivity/high specificity analysis of ccfRNAs that are specifically and overexpressed in testicular germ cell tumour (TGCT) and prostate cancer (PCa) respectively.

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз